Orchestra BioMed Email Formats
Biotechnology Research • 
United States • 51-100 Employees
Orchestra BioMed Email Formats
Orchestra BioMed uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@orchestrabiomed.com), used 55.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@orchestrabiomed.com | 55.6% |
{first name}{last name} | johndoe@orchestrabiomed.com | 33.3% |
{first name}.{last name} | john.doe@orchestrabiomed.com | 5.6% |
{last name}{last name} | doedoe@orchestrabiomed.com | 3.7% |
{first initial} | j@orchestrabiomed.com | 1.9% |
Key Contacts at Orchestra BioMed
Pam Yanchik Connealy
Director Board Of Directors & Audit Committee Chair
Donald Klein
Senior Director Of Marketing
Gregory A. Kopia
Director Of Preclinical Development - Focal Therapies
Stijn Kramer
Director, Field Clinical Engineering
Joshua Fichmann
Director Of Sec Reporting & Technical Accounting
Jason Aryeh
Director
Yuval Mika
General Manager And Chief Technology Officer, Bioelectronic Therapies
Norbert Rosenthal
Director, Bioelectronic Therapies
Yuri V. Ilitchev
Director, Analytical Operations
Company overview
| Headquarters | United States |
| Phone number | +13057739323 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2017 |
| Employees | 51-100 |
| Socials |
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Orchestra BioMed has 38 employees across 12 departments.
Departments
Number of employees
Funding Data
Explore Orchestra BioMed's funding history, including investment rounds, total capital raised, and key backers.
Orchestra BioMed Tech Stack
Discover the technologies and tools that power Orchestra BioMed's digital infrastructure, from frameworks to analytics platforms.
CDN
Security
CMS
JavaScript libraries
JavaScript libraries
CDN
JavaScript libraries
Analytics
Miscellaneous
Security
Analytics
UI frameworks
Kenya
Türkiye
Australia
United Kingdom
Frequently asked questions
4.8
40,000 users
